Stockscreener 앱 받기
10.03
2.05%
-0.21
시간 외 거래:
10.03
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics director Charles W. Newton sells $5,521 in shares - Investing.com
Insider Sell: Charles Newton Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline - Markets Mojo
Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside - TradingView
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline AdvancesNon-GAAP Earnings - newsline.com
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics director Nima sells $28,166 in company stock By Investing.com - Investing.com Nigeria
KROS: KER-065 targets muscle regeneration in DMD, with strong early data and a solid financial runway - TradingView
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com
Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale - Stock Titan
Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade - Stock Titan
Keros Therapeutics (KROS) Faces Selling Pressure as Shares Approach Key SupportATR Trailing Stop - newsline.com
How (KROS) Movements Inform Risk Allocation Models - Stock Traders Daily
Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director granted RSUs and options | KROS Insider Trading - Stock Titan
Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards - Stock Titan
Keros Therapeutics (KROS) grants RSUs and stock options to director - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant - Stock Titan
Keros Therapeutics (KROS) director awarded RSUs and stock options - Stock Titan
Keros Therapeutics Stockholders Approve Directors and Governance Matters - TipRanks
Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside - TradingView
Keros Therapeutics CEO to Present at Goldman Sachs Conference - The Globe and Mail
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Keros Therapeutics CEO to speak at Goldman Sachs health conference - Stock Titan
Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat - Stock Titan
KROS Q1 2026 Earnings: EPS Miss of $1.21 as Pre-Revenue Biotech Continues Clinical InvestmentTech Earnings Analysis - newsline.com
Keros Therapeutics (KROS) Edges Lower Near Key Support ZoneDescending Triangle - The Legal Advocate
Keros Therapeutics (KROS) Edges Higher Amid Consolidation Near Key ResistanceResistance Breakout Stocks - The Legal Advocate
Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily
Keros Therapeutics (KROS) Edges Higher as Biotech Sector Shows Mixed SignalsVolume Breakout Ideas - newsline.com
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail
Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports
Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail
1.27%
1.43%
자본화:
|
볼륨(24시간):